The ongoing legal battle between Moderna and Arbutus Biopharma took a significant turn as the U.S. Court of Appeals for the Federal Circuit examined a ruling that held Moderna accountable for patent infringement claims related to its COVID-19 vaccines. Central to the discussions on Thursday was whether Moderna’s activities should be deemed as being conducted “for the government” as per a statutory defense often invoked by contractors engaged in government projects.
The Federal Circuit panel scrutinized the lower court’s earlier decision, probing the interpretation of “for the government” in the context of the U.S. government’s involvement in vaccine development under initiatives like Operation Warp Speed. This inquiry is particularly relevant because if Moderna’s efforts are deemed to align with government-directed activities, the company could be shielded from liability under 28 U.S.C. § 1498, a statute allowing contractors to avoid infringement claims when acting under a government contract. Details of the court’s considerations are reported by Law360.
Moderna’s defense hinges on the extraordinary circumstances of its collaboration with various government agencies to develop vaccines swiftly during the pandemic. The company argues that its actions consistently met the government’s objectives, a point that judges are weighing closely. Key aspects of the statute, including the nature of “authorization or consent” from the government, are pivotal in their analysis.
This case has broader implications for the pharmaceutical industry and government contractors, as it tests the limits of legal protections available to companies operating under government directives. The decision could influence future collaborations and patent strategy, especially in sectors where government and private efforts frequently intersect, such as defense and healthcare.
Additionally, this situation underscores larger questions about intellectual property rights during public health emergencies. Similar legal and ethical considerations have arisen worldwide, prompting legal experts and policymakers to reassess how intellectual property laws apply in urgent, high-stakes scenarios. For a broader exploration of these dynamics, Reuters provides an in-depth perspective in their coverage of related cases in the pharmaceutical industry.